CRISPR THERAPEUTICS AG Increase (Decrease) in Accounts Payable and Accrued Liabilities
CRISPR THERAPEUTICS AG (CRSP) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$18.32 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-03
- CRISPR THERAPEUTICS AG increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was -$5.31M.
- CRISPR THERAPEUTICS AG increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$13.02M, a 130.27% decline year-over-year.
- CRISPR THERAPEUTICS AG increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $4.42M.
- CRISPR THERAPEUTICS AG increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $12.18M.
- CRISPR THERAPEUTICS AG increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $44.89M.
- CRISPR THERAPEUTICS AG increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was -$27.28M.
- CRISPR THERAPEUTICS AG increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was -$20.25M, a 492.08% decline from fiscal 2022.
- CRISPR THERAPEUTICS AG increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $5.16M, a 86.23% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$5.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$18.32M 10-Q · filed 2026-08-03 | -$13.90M derived: sum of 3 quarters · filed 2026-08-03 | -$1.73M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | -$13.02M 10-Q · filed 2026-05-04 | -$8.59M derived: sum of 2 quarters · filed 2026-05-04 | $3.58M derived: sum of 3 quarters · filed 2026-05-04 | -$11.12M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $4.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $16.60M derived: sum of 2 quarters · filed 2026-02-12 | $1.90M derived: sum of 3 quarters · filed 2026-08-03 | $44.89M 10-K · filed 2026-02-12 |
| 2025-09-30 | $12.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$2.52M derived: sum of 2 quarters · filed 2026-08-03 | $40.47M 10-Q · filed 2025-11-10 | $32.62M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | -$14.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $28.30M 10-Q · filed 2026-08-03 | $20.45M derived: sum of 3 quarters · filed 2026-08-03 | -$17.71M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $43.00M 10-Q · filed 2026-05-04 | $35.15M derived: sum of 2 quarters · filed 2026-05-04 | -$3.01M derived: sum of 3 quarters · filed 2026-05-04 | $6.27M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | -$7.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$46.01M derived: sum of 2 quarters · filed 2026-02-12 | -$36.73M derived: sum of 3 quarters · filed 2026-02-12 | -$27.28M 10-K · filed 2026-02-12 |
| 2024-09-30 | -$38.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$28.88M derived: sum of 2 quarters · filed 2025-11-10 | -$19.43M 10-Q · filed 2025-11-10 | -$28.62M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | $9.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $18.72M 10-Q · filed 2025-08-04 | $9.53M derived: sum of 3 quarters · filed 2026-02-12 | -$15.16M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | $9.44M 10-Q · filed 2025-05-06 | $252.00K derived: sum of 2 quarters · filed 2026-02-12 | -$24.44M derived: sum of 3 quarters · filed 2026-02-12 | -$36.02M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | -$9.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$33.88M derived: sum of 2 quarters · filed 2026-02-12 | -$45.46M derived: sum of 3 quarters · filed 2026-02-12 | -$20.25M 10-K · filed 2026-02-12 |
| 2023-09-30 | -$24.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$36.27M derived: sum of 2 quarters · filed 2024-11-05 | -$11.06M 10-Q · filed 2024-11-05 | -$42.15M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | -$11.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $13.64M 10-Q · filed 2024-08-05 | -$17.46M derived: sum of 3 quarters · filed 2025-02-11 | $10.50M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | $25.21M 10-Q · filed 2024-05-08 | -$5.88M derived: sum of 2 quarters · filed 2025-02-11 | $22.07M derived: sum of 3 quarters · filed 2025-02-11 | $31.99M derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-31 | -$31.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | -$3.14M derived: sum of 2 quarters · filed 2025-02-11 | $6.78M derived: sum of 3 quarters · filed 2025-02-11 | $5.16M 10-K · filed 2025-02-11 |
| 2022-09-30 | $27.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $37.88M derived: sum of 2 quarters · filed 2023-11-06 | $36.26M 10-Q · filed 2023-11-06 | $59.04M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | $9.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $8.30M 10-Q · filed 2023-08-07 | $31.08M derived: sum of 3 quarters · filed 2024-02-21 | $32.39M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | -$1.62M 10-Q · filed 2022-05-09 | $21.16M derived: sum of 2 quarters · filed 2024-02-21 | $22.47M derived: sum of 3 quarters · filed 2024-02-21 | $41.67M derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | $22.78M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $24.09M derived: sum of 2 quarters · filed 2024-02-21 | $43.28M derived: sum of 3 quarters · filed 2024-02-21 | $37.51M 10-K · filed 2024-02-21 |
| 2021-09-30 | $1.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $20.50M derived: sum of 2 quarters · filed 2022-11-01 | $14.73M 10-Q · filed 2022-11-01 | $23.09M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $19.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $13.43M 10-Q · filed 2022-08-08 | $21.78M derived: sum of 3 quarters · filed 2023-02-21 | $25.96M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | -$5.77M 10-Q · filed 2022-05-09 | $2.58M derived: sum of 2 quarters · filed 2023-02-21 | $6.76M derived: sum of 3 quarters · filed 2023-02-21 | $22.47M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $8.35M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $12.53M derived: sum of 2 quarters · filed 2023-02-21 | $28.24M derived: sum of 3 quarters · filed 2023-02-21 | $25.75M 10-K · filed 2023-02-21 |
| 2020-09-30 | $4.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $19.89M derived: sum of 2 quarters · filed 2021-11-03 | $17.39M 10-Q · filed 2021-11-03 | $22.00M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $15.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $13.22M 10-Q · filed 2021-07-29 | $17.82M derived: sum of 3 quarters · filed 2022-02-15 | $19.09M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | -$2.50M 10-Q · filed 2021-04-27 | $2.11M derived: sum of 2 quarters · filed 2022-02-15 | $3.38M derived: sum of 3 quarters · filed 2022-02-15 | $5.85M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $4.61M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $5.87M derived: sum of 2 quarters · filed 2022-02-15 | $8.35M derived: sum of 3 quarters · filed 2022-02-15 | $5.03M 10-K · filed 2022-02-15 |
| 2019-09-30 | $1.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | $3.74M derived: sum of 2 quarters · filed 2020-10-28 | $420.00K 10-Q · filed 2020-10-28 | $4.55M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-06-30 | $2.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-27 | -$849.00K 10-Q · filed 2020-07-27 | $3.28M derived: sum of 3 quarters · filed 2021-02-16 | $7.50M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-03-31 | -$3.32M 10-Q · filed 2020-04-28 | $804.00K derived: sum of 2 quarters · filed 2021-02-16 | $5.02M derived: sum of 3 quarters · filed 2021-02-16 | $9.22M derived: sum of 4 quarters · filed 2021-02-16 |
| 2018-12-31 | $4.13M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | $8.35M derived: sum of 2 quarters · filed 2021-02-16 | $12.55M derived: sum of 3 quarters · filed 2021-02-16 | $12.11M 10-K · filed 2021-02-16 |
| 2018-09-30 | $4.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-28 | $8.42M derived: sum of 2 quarters · filed 2019-10-28 | $7.98M 10-Q · filed 2019-10-28 | $10.13M derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-06-30 | $4.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-29 | $3.76M 10-Q · filed 2019-07-29 | $5.91M derived: sum of 3 quarters · filed 2020-02-12 | $5.04M derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-03-31 | -$439.00K 10-Q · filed 2019-04-29 | $1.71M derived: sum of 2 quarters · filed 2020-02-12 | $833.00K derived: sum of 3 quarters · filed 2020-02-12 | $2.38M derived: sum of 4 quarters · filed 2020-02-12 |
| 2017-12-31 | $2.15M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-12 | $1.27M derived: sum of 2 quarters · filed 2020-02-12 | $2.82M derived: sum of 3 quarters · filed 2020-02-12 | -$831.00K 10-K · filed 2020-02-12 |
| 2017-09-30 | -$876.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $669.00K derived: sum of 2 quarters · filed 2018-11-07 | -$2.98M 10-Q · filed 2018-11-07 | -$2.39M derived: sum of 4 quarters · filed 2019-02-25 |
| 2017-06-30 | $1.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | -$2.10M 10-Q · filed 2018-08-07 | -$1.52M derived: sum of 3 quarters · filed 2019-02-25 | -$3.23M derived: sum of 4 quarters · filed 2019-02-25 |
| 2017-03-31 | -$3.65M 10-Q · filed 2018-05-08 | -$3.06M derived: sum of 2 quarters · filed 2019-02-25 | -$4.78M derived: sum of 3 quarters · filed 2019-02-25 | -$1.74M derived: sum of 4 quarters · filed 2019-02-25 |
| 2016-12-31 | $585.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | -$1.13M derived: sum of 2 quarters · filed 2019-02-25 | $1.90M derived: sum of 3 quarters · filed 2019-02-25 | $3.86M 10-K · filed 2019-02-25 |
| 2016-09-30 | -$1.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $1.32M derived: sum of 2 quarters · filed 2017-11-08 | $3.27M 10-Q · filed 2017-11-08 | $8.48M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | $3.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $4.99M 10-Q · filed 2017-08-10 | $10.19M derived: sum of 3 quarters · filed 2018-03-08 | |
| 2016-03-31 | $1.96M 10-Q · filed 2017-05-11 | $7.16M derived: sum of 2 quarters · filed 2018-03-08 | ||
| 2015-12-31 | $5.20M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $7.71M 10-K · filed 2018-03-08 | ||
| 2015-09-30 | $2.50M 10-Q · filed 2016-11-22 | |||
| 2014-12-31 | $1.58M 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |